VivoSeq
Other

Hematologic Disease

20

Pipeline Programs↗

6

Active Trials↗

15

Companies Involved↗

Hematologic Disease is an emerging landscape with 20 programs across 15 companies. The most active players are Chongqing Precision Biotech Co., Ltd, Novartis, Sanofi. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

0/100

Mech. Concentration

10/100

Completion Rate

50/100

Attrition Rate

27/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Chongqing Precision Biotech Co., Ltd

1 program

Phase 1Novartis logo

Novartis

3 programs

Phase 2Sanofi logo

Sanofi

2 programs

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2E

Eastern Cooperative Oncology Group

1 program

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

76%

Small molecule

16 of 21 classified programs — the dominant modality here.

24%ALL OTHERSMonoclonal antibody210%Cell therapy210%Protein / enzyme15%

Small molecule leads; the ring shows all 21 classified programs, each share of the total. Modality classified for 100% of 22 pipeline programs.

Analysis

Trial Status

15

clinical trials

Completed4 · 27%
Recruiting4 · 27%
Terminated4 · 27%
Unknown status1 · 7%
Not yet recruiting1 · 7%
Enrolling by invitation1 · 7%

Clinical Trials

Trial Activity

15 trials

CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
Recruiting·ZZhejiang University·Phase 1·NCT04662294·108 enrolled
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT06013423·54 enrolled
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Recruiting·—·Phase 2·NCT04099966·20 enrolled
CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases
Recruiting·ZZhejiang University·Phase 1/2·NCT05827835·30 enrolled
Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases
Not yet recruiting·—·Phase 2·NCT06480630·39 enrolled
Screening Protocol for Subjects Being Evaluated for National Heart, Lung and Blood Institute (NHLBI) Protocols
Enrolling by invitation·National Heart, Lung, and Blood Institute (NHLBI)·N/A·NCT00001620·10,000 enrolled
Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases
Completed·CCenter for Supporting Hematology-Oncology Trials·Phase 3·NCT00137787·51 enrolled
Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease
Completed·JJohns Hopkins University·Phase 2·NCT00010387·32 enrolled
Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease
Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00003913·390 enrolled
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00719888·135 enrolled
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases
Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00376519·3 enrolled
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases
Terminated·MMasonic Cancer Center, University of Minnesota·N/A·NCT02145039·2 enrolled
The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases
Terminated·SSemmelweis University·Phase 3·NCT01518959·31 enrolled
Stem Cell Transplant for Hematologic Diseases
Terminated·—·Phase 1/2·NCT00058825·27 enrolled
Donor Umbilical Cord Blood Transplant After Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Unknown status·CCancer Research UK·Phase 2·NCT00959231·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)